This data was collected at the last HCMA meeting!

PRINCETON, N.J., Nov. 5 /PRNewswire-FirstCall/ - Researchers at Zargis
Medical Corp., a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE),
announced today the results of a clinical study that demonstrated that a
computer-assisted heart sounds analysis algorithm could identify those
patients flagged by a cardiologist as having apical systolic murmurs that were
louder on standing than reclining, a cardinal sign of obstructive HCM. HCM is
implicated in one third of the cases of sudden cardiac death in young
athletes.
The full report of this study will appear in the forthcoming volume of the
Texas Heart Institute Journal.
The study involved twelve volunteer subjects who had been previously
diagnosed with HCM, of which four reported obstructive HCM. Twenty-second
recordings were obtained at each of four standard auscultatory locations in
two postures: standing and reclining. Detailed auscultatory findings were
derived by listening to the heart sound recordings by a cardiologist who was
blinded to the study design. The recordings were analyzed by a computer
algorithm that detects and identifies heart sounds and murmurs, and provides
quantitative measures of the heart sounds. The algorithm results were compared
with the auscultatory findings provided by the cardiologist.
A high degree of concordance between the cardiologists' auscultatory
findings and computer analyses was obtained. The systolic energy was found to
correlate well with judgments of the relative loudness of murmurs in different
postures. Those three subjects which were flagged by the cardiologist as
having apical systolic murmurs that were louder on standing, were identified
by the algorithm as having apical systolic murmurs with higher systolic
energies in the standing posture.
These results demonstrate that there are detectable acoustic features of
heart sound recordings that are associated with auscultatory findings of
obstructive HCM.
According to Managing Director John Kallassy, "There is a clear and
immediate need for a cost effective screening method that could help to
identify young athletes at risk of sudden cardiac death due to HCM. This
result holds promise of developing a cost-effective and readily available test
for screening young athletes."

About Zargis Medical Corp.
Zargis Medical Corp. was formed in January 2001 when Siemens Corporate
Research Inc., a subsidiary of Siemens AG (NYSE: SI), and Speedus Corp.
(Nasdaq: SPDE) co-invested in Zargis to further develop and commercially
market an advanced acoustic technology for detecting abnormalities identified
through analysis of heart sounds. Based in Princeton, New Jersey, Zargis is
developing advanced diagnostic decision support products and services for
primary care physicians, cardiologists and other healthcare professionals.
For additional information on Speedus Corp. or Zargis Medical, contact
John Kallassy, 718.567.4358, [email protected], or visit their websites at
http://www.speedus.com and http://www.zargis.com.
For additional information on Siemens Corporate Research, visit their
website at http://www.scr.siemens.com.

Statements contained herein that are not historical facts, including but
not limited to statements about the Company's product, corporate identity and
focus, may be forward-looking statements that are subject to a variety of
risks and uncertainties. There are a number of important factors that could
cause actual results to differ materially from those expressed in any
forward- looking statements made by the Company, including, but not limited
to, the continuing development of the Company's sales, marketing and support
efforts.



SOURCE Zargis Medical Corp.